Perspectives in Managing Kidney Disease and Atherosclerotic Cardiovascular Disease.

IF 2.4 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiorenal Medicine Pub Date : 2024-01-01 Epub Date: 2024-06-14 DOI:10.1159/000539804
Tarlan Namvar, Matthew A Cavender, Eden Miller, Sherif Mehanna, Reese Ochsner, Dominic S Raj
{"title":"Perspectives in Managing Kidney Disease and Atherosclerotic Cardiovascular Disease.","authors":"Tarlan Namvar, Matthew A Cavender, Eden Miller, Sherif Mehanna, Reese Ochsner, Dominic S Raj","doi":"10.1159/000539804","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Chronic kidney disease (CKD) and atherosclerotic cardiovascular disease (ASCVD) share a complex and dependent link with each other and other cardiometabolic conditions. Currently, there is insufficient data regarding patient and provider perceptions about this important clinical overlap. This study sought to evaluate healthcare provider (HCP) and patient attitudes and perceptions about CKD and ASCVD, including risk, diagnosis, and management of both conditions.</p><p><strong>Methods: </strong>Cross-sectional surveys of 58 nephrologists and 74 cardiologists who treat patients with CKD and ASCVD and 195 patients who self-reported having CKD and ASCVD were conducted in the USA between May and June 2021.</p><p><strong>Results: </strong>Most nephrologists agreed that the presence of cardiometabolic comorbidities increased patients' risk of developing CKD; 86% agreed that type 2 diabetes increased the risk, and 67% agreed that ASCVD increased the risk. However, only 52% of the nephrologists reported they typically discuss the risk of developing CKD with patients prior to diagnosing them. Slightly more than one-third of patients (35%) reported their HCP discussed other conditions' impact on the development of CKD; of all HCPs surveyed, nephrologists were the least likely to discuss CKD risk with their patients. Most nephrologists (83%) also reported they recommended lifestyle modification to patients; however, only about half of patients (53%) reported they were currently using a lifestyle change to treat CKD and/or ASCVD.</p><p><strong>Conclusion: </strong>Although CKD and ASCVD are known to have a bidirectional relationship, HCPs in our study did not report routinely educating patients about the risk of developing one or both conditions. As HCPs with perhaps the deepest understanding of the interplay between CKD and cardiorenal comorbidities, nephrologists are well positioned to help patients understand the link between cardiovascular and renal health, help identify strategies to limit risk, and appropriately treat the conditions.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"426-436"},"PeriodicalIF":2.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiorenal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000539804","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Chronic kidney disease (CKD) and atherosclerotic cardiovascular disease (ASCVD) share a complex and dependent link with each other and other cardiometabolic conditions. Currently, there is insufficient data regarding patient and provider perceptions about this important clinical overlap. This study sought to evaluate healthcare provider (HCP) and patient attitudes and perceptions about CKD and ASCVD, including risk, diagnosis, and management of both conditions.

Methods: Cross-sectional surveys of 58 nephrologists and 74 cardiologists who treat patients with CKD and ASCVD and 195 patients who self-reported having CKD and ASCVD were conducted in the USA between May and June 2021.

Results: Most nephrologists agreed that the presence of cardiometabolic comorbidities increased patients' risk of developing CKD; 86% agreed that type 2 diabetes increased the risk, and 67% agreed that ASCVD increased the risk. However, only 52% of the nephrologists reported they typically discuss the risk of developing CKD with patients prior to diagnosing them. Slightly more than one-third of patients (35%) reported their HCP discussed other conditions' impact on the development of CKD; of all HCPs surveyed, nephrologists were the least likely to discuss CKD risk with their patients. Most nephrologists (83%) also reported they recommended lifestyle modification to patients; however, only about half of patients (53%) reported they were currently using a lifestyle change to treat CKD and/or ASCVD.

Conclusion: Although CKD and ASCVD are known to have a bidirectional relationship, HCPs in our study did not report routinely educating patients about the risk of developing one or both conditions. As HCPs with perhaps the deepest understanding of the interplay between CKD and cardiorenal comorbidities, nephrologists are well positioned to help patients understand the link between cardiovascular and renal health, help identify strategies to limit risk, and appropriately treat the conditions.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
管理肾病和动脉粥样硬化性心血管疾病的视角。
简介慢性肾脏病(CKD)和动脉粥样硬化性心血管疾病(ASCVD)之间以及与其他心脏代谢疾病之间存在着复杂的依赖关系。目前,有关患者和医疗服务提供者对这一重要临床重叠的看法的数据尚不充分。本研究旨在评估医疗服务提供者(HCP)和患者对慢性肾脏病和 ASCVD 的态度和看法,包括这两种疾病的风险、诊断和管理:方法:2021 年 5 月至 6 月期间,在美国对治疗慢性肾脏病和 ASCVD 患者的 58 位肾病专家和 74 位心脏病专家以及 195 位自称患有慢性肾脏病和 ASCVD 的患者进行了横断面调查:大多数肾脏病专家都认为,心脏代谢合并症的存在会增加患者罹患 CKD 的风险;86% 的肾脏病专家认为 2 型糖尿病 (T2D) 会增加风险,67% 的肾脏病专家认为 ASCVD 会增加风险。然而,只有 52% 的肾科医生表示,他们通常会在诊断患者之前与患者讨论其罹患 CKD 的风险。略高于三分之一的患者(35%)称他们的保健医生讨论了其他疾病对 CKD 发展的影响;在所有接受调查的保健医生中,肾病专家最不可能与患者讨论 CKD 风险。大多数肾科医生(83%)还称他们向患者推荐改变生活方式;然而,只有约一半的患者(53%)称他们目前正在采用改变生活方式的方法来治疗慢性肾功能衰竭和/或急性心血管疾病:结论:尽管众所周知慢性肾脏病和心血管内科疾病之间存在双向关系,但在我们的研究中,保健医生并没有报告说他们会定期向患者讲解患上一种或两种疾病的风险。作为对 CKD 和心肾合并症之间的相互作用有着最深刻理解的保健医生,肾脏病医生完全有能力帮助患者了解心血管健康和肾脏健康之间的联系,帮助确定限制风险的策略,并适当治疗这些疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cardiorenal Medicine
Cardiorenal Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-UROLOGY & NEPHROLOGY
CiteScore
5.40
自引率
2.60%
发文量
25
审稿时长
>12 weeks
期刊介绍: The journal ''Cardiorenal Medicine'' explores the mechanisms by which obesity and other metabolic abnormalities promote the pathogenesis and progression of heart and kidney disease (cardiorenal metabolic syndrome). It provides an interdisciplinary platform for the advancement of research and clinical practice, focussing on translational issues.
期刊最新文献
A New Era in the Management of Cardiorenal Syndrome: The Importance of Cardiorenal Units. Association of Liver Fibrosis Markers with Mortality Outcomes in Patients with Chronic Kidney Disease and Coronary Artery Disease: Insights from the NHANES 1999-2018 Data. EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease (CKD) and Heart Failure. Cardiorenal disease and heart failure with preserved ejection fraction: Two sides of the same coin. Changes in Antigen Carbohydrate 125 in Patients Receiving Dapagliflozin Following an Admission for Acute Heart Failure.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1